| Literature DB >> 33789597 |
Mohammad Reza Khalili1, Athar Zareei2.
Abstract
BACKGROUND: Closantel is the best-known anti-parasitic medicine for veterinarians, which is contraindicated in humans. After reviewing the literature on ocular toxicity following mistaken usage of Closantel in humans, this report was found as the first complete restoration of visual function after Closantel intoxication. This report could be useful in anticipating the possibility of a further improvement based on a dose-response relationship. An important point of this report is the apparent reversibility of the vision and Electrophysiological parameters after Closantel intoxication and blindness. To conclude, the present case report demonstrates the importance of immediate referral and management in Closantel intoxication to avoid the long-term adverse effects of drug on visual function. CASEEntities:
Keywords: Case report; Closantel; Electroretinography; Ocular; Toxicity; Vision
Mesh:
Substances:
Year: 2021 PMID: 33789597 PMCID: PMC8010975 DOI: 10.1186/s12886-021-01916-4
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1a: Normal ERG responses and patient’s ERG responses 1 week after Closantel ocular toxicity. All six standard in the normal person of the same age which obtained with the same instrument(a) and all six standard ERG respons of the patient showed remarkable declines in both eyes(b)
Fig. 2The apparent improvement in Scotopic ERG responses in three different times after taking closantel and a normal scotopic ERG response in both eyes. Scotopic recorded 1 week after Closantel toxicity(a),Scotopic ERG recorded 1 month after Closantel toxicity(b), Scotopic ERG response 3 years after Closantel toxicity(c), normal Scotopic ERG in the normal individual of the same age with the same instrument(d)
Fig. 3The apparent improvement in Photopic ERG responses (3.0 Flicker 30 Hz) ERG in three different times after taking closantel and a normal Photopic ERG response in both eyes. Photopic ERG responses 1 week after Closantel toxicity(a), Photopic ERG responses recorded 1 month after Closantel toxicity(b), Photopic ERG responses recorded 3 years after Closantel toxicity(c) and normal Photopic responses in the normal individual of the same age with the same instrument(d)
Fig. 4Fundus photography after restored vision during the follow-up examination. Right eye (a), Left eye (b)
Fig. 5Macular OCT after restored vision during the follow-up examination. Right eye (OD), Left eye (OS)
Previous case reports and case series of closantel toxicity (1993–2020)
| Patients Gender | Author | Cumulative dose | time | treatment | Final VA | Clinical assessment and Paraclinical tests |
|---|---|---|---|---|---|---|
| F(3) | Badrane et al. (2013) | N/A | 24 h | Oral vitamins b1, b6,b12 | blindness | bilateral mydriasis no pupillary reflex severe papilloedema radiological investigations:normal biological exams:normal |
M (40) M (44) | Badrane et al. (2013) | N/A | One week One week | Unknown | blindness | Fundos photograph: normal visual feld: scotoma Laboratory tests: normal |
| F(5) | Essbar et al. (2014) | 500 mg/day for 8 day | 8 days | Glucocorticoids, vitamin B12,vitamin K correction of blood, coagulation parameters,normalization of liver enzymes | blindness | bilateral mydriasis,no pupillary reflex,papilledema ERG: decreased retinal activity VEP: decreased amplitude and delayed peak latency hepatic enzymes: acute increase leukocytosis anemia coagulopathy |
| M(50) | Koziolek et al. (2015) | 2700 mg of mebendazol,1800 mg of closantel | 7 days | Plasma Exchange in 5 sessions | OU: Hand movements (before treatment) OU: 20/25 | VF: markedly constricted at outer margins VEP: decreased amplitude and delayed peak latency ERG:decreased photoreceptor signal amplitude and normal latency After treatment: mfERG: showed residual central amplitude impairment. |
| M(34) | Tabatabaei et al. (2016) | three 500 mg tablets | 10 days | injections 20,000 units daily for 3 days 1 mg/kg oral prednisolone 1 g intravenous methylprednisolone acetate for 3 days | no light perception (NLP) | macular OCT: disruption in ORL outer retina ERG: severe decreased photopic and scotopic respons VEP: decreased amplitude and delayed peak latency serum hemoglobin, 11 mg/dl ALT: increase more than two times AST:increase more than two times |
F(28) F(22) F(25) F(38) F(24) | Hoen et al. (1993) Asoklis et al. (2015) Asoklis et al. (2018) | 3 tablets 3 tablets 3 tablets 3 tablets 3.5 tablets | N/A | N/A | OD:20/63 OS: 20/200 OD:20/25 OS: 20/40 OD: 20/20 OS: 20/20 OD: 20/40 OS: 20/40 OD: 20/25 OS: 20/25 | The last examination reported: All patients reported Limited visual function VF: markedly constricte fundos photography: changes in the fundus VEP: decreased amplitude and delayed peak latency SD-OCT: thinner retinal pigment epithelium, photoreceptor وouter nuclear, outer plexiform, and inner nuclear retinal layers |
F Famale, M Male, Time The time between taking Closantel and starting treatment, OCT optical coherence tomography, ERG Electroretinogram, mfERG multifocal Electroretinogram, VEP visual evoked potential, ALT liver aminotransferases (alanine), AST aspartate aminotransferase, SD-OCT spectral domain optical coherence tomo-graph